Johnston Christopher D, Wargo Jennifer A
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77006, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77006, USA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77006, USA.
Trends Immunol. 2024 Dec;45(12):931-933. doi: 10.1016/j.it.2024.11.007. Epub 2024 Nov 27.
In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to deliver cancer neoantigen payloads, stimulating antigen-specific CD4 and CD8 T cells and mediating antitumor immunity in preclinical models of colorectal cancer and melanoma.
在抗击癌症的战斗中，研究人员正在探索将工程菌用作活体药物。雷登蒂及其同事证明，可对大肠杆菌Nissle 1917（EcN）进行工程改造，以递送癌症新抗原有效载荷，在结直肠癌和黑色素瘤的临床前模型中刺激抗原特异性CD4和CD8 T细胞并介导抗肿瘤免疫。
